The authors sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25% and 45%.
After completion of a successful doubleblind, double-crossover study in Europe (FIX-
HF-4 [Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With
Moderate-to-Severe Heart Failure] study) (4) and a pilot study in the United States (5), the randomized FIX-HF-5 trial was performed to study the safety and efficacy of CCM in patients with New York Heart Association (NYHA) functional class III or IV symptoms and reduced EF (6) . That 428-patient study met its primary safety endpoint (a noninferiority assessment of the composite of all-cause mortality and all-cause hospitalizations).
However, the primary efficacy endpoint, responders' analysis of changes in ventilatory anaerobic threshold on cardiopulmonary exercise stress testing (CPX), was not met (6) . An exploratory, hypothesisgenerating subgroup analysis showed significant treatment effects on primary and secondary endpoints in patients with EFs ranging from 25% to 45% (7).
We therefore designed the FIX-HF-5 confirmatory study (FIX-HF-5C study) to prospectively test the efficacy and safety of CCM in patients with EF ranging from 25% to 45% (8) . A Bayesian statistical analysis plan was employed to take advantage of data available from the original study.
METHODS STUDY DESIGN.
This was a prospective, randomized study of optimal medical therapy (OMT) alone (control group) versus OMT plus CCM (CCM treatment group) in patients with medically refractory, but ambulatory heart failure (NYHA functional class III or IV) with EF ranging from 25% to 45%. The details of the study design have been provided previously (8) .
As will be discussed in the following text, the final design was influenced by the fact that the Optimizer system (Impulse Dynamics, Orangeburg, New York) was designated as eligible for the Expedited Access
Pathway of the U.S. Food and Drug Administration (FDA) (9) because it potentially provides a treatment
for an underserved population. The study was registered on ClinicalTrials.gov (NCT01381172).
STUDY POPULATION. The inclusion and exclusion criteria are summarized in Online Table 1 (8) . Patients with NYHA functional class III or ambulatory class IV heart failure despite OMT, an EF ranging from 25% to 45% as determined by an echocardiographic core laboratory, and normal sinus rhythm with QRS duration <130 ms were eligible for the study. Unless there were extenuating circumstances, patients with EF #35% were required to have an implantable cardiac-defibrillator (ICD) according to published guidelines.
The overall study flow is summarized in Online Figure 2 , and the detailed schedule of events is summarized in Online The device and implantation procedure have been detailed previously (2, 5, 10) . In brief, an atrial lead is used for sensing and is placed in the same manner as for standard pacemakers and defibrillators. Two ventricular leads, used for both sensing local electrical activity and CCM signal delivery, are placed on the right ventricular septum. The device was programmed to deliver CCM signals for 5 1-h periods spaced equally throughout the 24 h of the day.
EXERCISE TESTING AND CORE LABORATORY.
Rigorous procedures applied by a core laboratory served to optimize test quality and achieve maximal effort from each patient. These measures included: 
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Abraham et al. Among the additional pre-specified analyses (8) were assessments of the CCM treatment effects in Secondary safety analyses included all-cause mortality, cardiac mortality, heart failure mortality, all-cause hospitalizations, cardiac-related hospitalizations, heart failure-related hospitalizations, and overall incidence and seriousness of adverse events.
The survival analyses were performed using KaplanMeier analysis and the adverse events were tabulated by seriousness and treatment group using the Fisher exact test. and withdrawn after being randomized, 1 was discovered to have an additional abandoned ICD lead and the implant was canceled, and 2 decided not to undergo the implant.
Baseline characteristics of subjects in the current study and in the designated subgroup of subjects of the prior FIX-HF-5 study with EF $25% are summarized in Table 1 . Among the 21 baseline characteristics examined, a few differences existed within treatment groups between patients of the current (FIX-HF-5C) and original (FIX-HF-5) studies. Although statistically
Cardiac Contractility Modulation in Heart Failure -2 0 1 8 : ---different, the quantitative differences were generally small and were not considered clinically significant. Figure 2A and
Online Table 4 . The probability that CCM treatment is superior to control is 0.989, which exceeds the The conclusion of CCM superiority with respect to mean pVO 2 was consistent across all sensitivity analyses (details not shown). In addition, it was noted that the primary analysis would achieve statistical significance with any borrowing weight of 0.11 or 
Abraham et al. Table 7 ; aside from EF, there were no significant differences between groups or between treatment groups. Treatment effects (i.e., the mean differences and 95% CIs of control and treatment groups) on the primary endpoint (pVO 2 ) and 2 secondary endpoints (MLWHFQ and NYHA functional class) in the 2 EF subgroups are summarized in Figure 4 . As seen, better efficacy results were obtained in the CCM group in all cases.
FIGURE 2 Primary Efficacy Results
(A) Between group-differences in peak VO 2 over time.
(B) 24-week between-group treatment effects in FIX-HF-5 subgroup alone, FIX-HF-5C alone, and Bayesian result.
FI GURE 3 Secondary Efficacy Results
Treatment effects at 24 weeks in FIX-HF-5, FIX-HF-5C separately and pooled for (A) Minnesota Living With Heart Failure questionnaire (MLWHFQ) and (B) 6-min hall walk (6MHW) test.
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6MHW improved more in patients with EF $35%
( Figure 4D ). Additional quantitative details are provided in Online Table 8 . Overall survival in the FIX-HF-5C cohort through 24 weeks was high in both groups (98% in treatment and Table 6 . CCM ¼ cardiac contractility modulation.
Abraham et al. Table 9 ). Finally, subgroup analysis showed that this improvement was mainly driven by a significant reduction in events for the EF 25% to 35% cohort (p ¼ 0.009).
ADJUDICATED SERIOUS ADVERSE EVENTS. Serious adverse events as adjudicated by the Clinical Events
Committee are summarized in Online Table 10 .
Overall, 19 control patients (22%) and 20
CCM-treatment patients (27%) experienced a serious adverse event. Seven control subjects (13%) versus 3 CCM treatment subjects (4%) had a worsening heart failure serious adverse event (p ¼ 0.34). There were no significant differences in any category between the treatment groups.
DISCUSSION
The results of the present unblinded study confirm that CCM is safe and significantly improves exercise 
, and CONTAC-CD study (0.8 ml/kg/min) (15).
Although these studies have different entry criteria, they do provide a basis for comparing the effects of CCM to CRT.
The current study also identified a significant reduction of the composite of cardiovascular death and heart failure hospitalizations, which are important therapeutic targets for this therapy. Although the current study was too short in duration and included too few patients to fully address survival benefit, prior studies have provided evidence of beneficial effects on survival and hospitalization (16) (17) (18) (19) (20) . In addition, an ongoing multicenter registry study is underway in Europe (CCM-REG) to further address this issue.
SERVING AN UNMET NEED. CRT has long been available for patients with EF #35%, normal sinus rhythm, QRS duration $130 ms, and persistent NYHA
